Re‐Innovation in Clinical Trial Designs Based on Precision Therapy

This article, centered on precision therapy, argues that traditional disease-centered clinical trials are flawed with prolonged cycles, insufficient early-phase samples, and inflexible protocols, thus proposing the concept of "clinical trial re-innovation." It elaborates that this re-innovation, driven by biomarker technology, multi-arm multi-stage designs, and improved trial flexibility, is realized through innovative designs like basket, umbrella, and platform trials, and explores their application in multiple diseases with cases, aiming to advance precise and efficient clinical research and improve patient outcomes.

Authors

Institutions

Publication Details

Journal
Cancer Innovation
Published
2025-09-24
DOI
https://doi.org/10.1002/cai2.70028
Citations
1
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
0.94
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Re‐Innovation in Clinical Trial Designs Based on Precision Therapy

Feng Chen, Jiachen Wang, Xun Kang, Wenbin Li et al.
1 citations
Cancer Innovation
Cancer Genomics and Diagnostics
0.94
article

Re‐Innovation in Clinical Trial Designs Based on Precision Therapy

Feng Chen, Jiachen Wang, Xun Kang, Wenbin Li, Shenglan Li, Zhuang Kang
article en
1 citations

Abstract

This article, centered on precision therapy, argues that traditional disease-centered clinical trials are flawed with prolonged cycles, insufficient early-phase samples, and inflexible protocols, thus proposing the concept of "clinical trial re-innovation." It elaborates that this re-innovation, driven by biomarker technology, multi-arm multi-stage designs, and improved trial flexibility, is realized through innovative designs like basket, umbrella, and platform trials, and explores their application in multiple diseases with cases, aiming to advance precise and efficient clinical research and improve patient outcomes.

Cancer InnovationVol. 4(5)
Capital Medical University (CN), Beijing Tian Tan Hospital (CN)
Openalex Percentile: Top 20%
Cancer Genomics and Diagnostics
0.94
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.